26
Views
0
CrossRef citations to date
0
Altmetric
Review

Therapeutic patents for cytomegalovirus

Pages 319-327 | Published online: 02 Mar 2005
 

Abstract

Cytomegalovirus (CMV) is an important pathogen with significant unmet medical need and an excellent pharmacoeconomic case for drug development. Nevertheless, 25 years of development has so far failed to bring to the market a single drug that is both potent and safe. This review will emphasise the potential offered by molecular biological approaches to improve this situation, illustrated by specific examples of inhibitors of CMV-encoded genes that have been identified recently. Thus, the novelty in the patent literature lies in the technology used to identify key antiviral targets for CMV and find inhibitory molecules. The author suggests that this approach has already provided sufficient novel lead compounds, which are potent inhibitors of their target enzymes. What is needed now is a concerted effort to move these compounds into early phase clinical trials, using applied molecular biology to measure viral load and so determine if any of these compounds can inhibit CMV in its natural habitat; the infected human.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.